BTK and mantle cell lymphoma: DD-03–171 is an optimized Bruton tyrosine kinase (BTK) inhibitor analog, which showed an enhanced anti-proliferation outcome on MCL cells in vitro through the degradation of BTK, Ikaros, and Aiolos (Dobrovolsky et al., 2019).